RecruitingRecruiting
Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
NCT04535882 · Showa Inan General Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis
About this study
Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group.
CD patients whose CDAI \>150 were divided into the active CD group.
Eligibility criteria
Inclusion Criteria:
* Patients whom possible UC or Crohn disease was suspected
Exclusion Criteria:
* other autoimmune diseases
* acute or chronic renal failure
* chronic heart diseases
* liver cirrhosis
* cancer
* acute or chronic infections
* ischemic colitis
* infectious colitis
Study design
Enrollment target: 300 participants
Age groups: child, adult, older_adult
Timeline
Starts: 2020-10-01
Estimated completion: 2026-12-31
Last updated: 2026-05-13
Interventions
Diagnostic Test: serum leucine-rich alpha-2 glycoprotein (LRG) levels
Primary outcomes
- • Serum LRG measurement (one year)
Sponsor
Showa Inan General Hospital · other
Contacts & investigators
ContactAkira Horiuchi, MD · contact · horiuchi.akira@sihp.jp · 81265822121
ContactMasashi Kajiyama, MD · contact · kajiyama.masashi@sihp.jp · 81265822121
All locations (1)
Showa Inan General HospitalRecruiting
Komagane, Nagano, Japan